These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8126524)

  • 1. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.
    Magnani HN; Ruys AH
    J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):254-5. PubMed ID: 8126524
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group.
    Adams HP; Woolson RF; Biller J; Clarke W
    Haemostasis; 1992; 22(2):99-103. PubMed ID: 1379970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemofiltration/haemodialysis in patients with heparin-associated thrombocytopenia.
    Chong BH; Jacques T
    Intensive Care Med; 1991; 17(7):437. PubMed ID: 1774405
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease.
    Ten Cate H; Henny CP; Büller HR; Ten Cate JW; Magnani HN
    Ann Neurol; 1984 Mar; 15(3):268-70. PubMed ID: 6721448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of heparin-induced thrombocytopenia with thrombosis by new heparinoid.
    Harenberg J; Zimmermann R; Schwarz F; Kübler W
    Lancet; 1983 Apr; 1(8331):986-7. PubMed ID: 6132291
    [No Abstract]   [Full Text] [Related]  

  • 6. Large-dose infusions of heparinoid ORG 10172 in ischemic stroke.
    Massey EW; Biller J; Davis JN; Adams HP; Marler JR; Goldstein LB; Alberts M; Bruno A
    Stroke; 1990 Sep; 21(9):1289-92. PubMed ID: 2396265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.
    Hoppensteadt D; Racanelli A; Walenga JM; Fareed J
    Semin Thromb Hemost; 1989 Oct; 15(4):378-85. PubMed ID: 2530633
    [No Abstract]   [Full Text] [Related]  

  • 8. Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. The program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
    Albanese MA; Clarke WR; Adams HP; Woolson RF
    Stroke; 1994 Sep; 25(9):1746-51. PubMed ID: 8073453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo activity of a new heparinoid.
    Ockelford PA; Carter CJ; Hirsh J
    Pathology; 1985 Jan; 17(1):78-81. PubMed ID: 4000717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of heparin fractions, fragments, and heparinoids.
    Messmore HL
    Semin Thromb Hemost; 1985 Apr; 11(2):208-12. PubMed ID: 2412297
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.
    Turpie AG; Levine MN; Hirsh J; Carter CJ; Jay RM; Powers PJ; Andrew M; Magnani HN; Hull RD; Gent M
    Lancet; 1987 Mar; 1(8532):523-6. PubMed ID: 2434815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
    Meuleman DG
    Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 14. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass.
    Doherty DC; Ortel TL; de Bruijn N; Greenberg CS; Van Trigt P
    Anesthesiology; 1990 Sep; 73(3):562-5. PubMed ID: 1697448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
    Adams HP; Woolson RF; Clarke WR; Davis PH; Bendixen BH; Love BB; Wasek PA; Grimsman KJ
    Control Clin Trials; 1997 Aug; 18(4):358-77. PubMed ID: 9257073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications.
    Henny CP; Ten Cate H; Ten Cate JW; Surachno S; van Bronswijk H; Wilmink JM; Ockelford PA
    Lancet; 1983 Apr; 1(8330):890-3. PubMed ID: 6132219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of subtypes of ischemic stroke: history of the trial of org 10172 in acute stroke treatment classification.
    Adams HP; Biller J
    Stroke; 2015 May; 46(5):e114-7. PubMed ID: 25813192
    [No Abstract]   [Full Text] [Related]  

  • 18. Immediate use of anticoagulants may not improve stroke outcomes.
    Am J Health Syst Pharm; 1998 Jun; 55(12):1240. PubMed ID: 9640462
    [No Abstract]   [Full Text] [Related]  

  • 19. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a low molecular weight preparation of heparin--ORG 10172 (Lomoparan) in the critically ill.
    John G; Shehabi Y; Mudaliar Y
    Anaesth Intensive Care; 1991 Nov; 19(4):588-91. PubMed ID: 1721505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.